Allogeneic GPRC5D-directed CART-cell therapy (Sana Biotechnology)

N/A

Report date: 2024/01/23 17:16:05

Base Information

Drug NameAllogeneic GPRC5D-directed CART-cell therapy (Sana Biotechnology)

Drug Alias NameAllogeneic GPRC5D-Directed CAR cell therapy (Sana Biotechnology)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionG-protein coupled receptor family C group 5member D modulatorsT lymphocyte replacements

TargetsG-protein coupled receptor family C group 5member D

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesSana Biotechnology Inc

China Registration ClassN/A

Develop Information

Active CompaniesSana Biotechnology Inc

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A